KRATEK OPIS PROJEKTA: Pandemija COVID-19 je izpostavila pomen pripravljenosti EU na izbruhe virusov. Raziskovalne infrastructure (RI) imajo pomembno vlogo pri podpori javnega zdravja, inovacij in raziskav, vendar je njihov vpliv omejen, če delujejo samostojno. Projekt EVORA (European Viral Outbreak Research Alliance) združuje tri RI (EVA, ERINHA-ESFRI in ELIXIR-ESFRI) s strokovnim znanjem in izkušnjami na področju biobank, zmogljivosti laboratorijev z visoko stopnjo biološke varnosti in upravljanja podatkov. Namen projekta EVORA, ki deluje v enotnem, interoperabilnem okviru, je povečati zmogljivost EU za pripravljenost in odzivanje na virusne bolezni. Prizadeva si za poenotenje dejavnosti RI, obravnavanje regulativnih in etičnih izzivov ter ustvarjanje sinergij s skupnim upravljanjem. Interoperabilne storitve EVORA bodo podpirale zdravstveno tehnologijo EU v pogojih odzivanja med krizami in ob pojavu virusnih bolezni. Z vzpostavitvijo trajnostnega zavezništva EVORA krepi povezanost področja RI, povečuje konkurenčnost evropskega raziskovalnega prostora in odpornost EU proti novim nalezljivim boleznim. SHORT DESCRIPTION: The COVID-19 pandemic has underscored the importance of EU readiness for viral outbreaks. Research infrastructures (RIs) play a vital role in supporting public health, innovation, and research, but their impact is limited when operating independently. The European Viral Outbreak Research Alliance (EVORA) project unites three RIs (EVA, ERINHA-ESFRI, and ELIXIR-ESFRI) with expertise in bio-banking, high containment facilities, and data management. Operating under a single, interoperable framework, EVORA aims to enhance EU capacity for preparedness and response to viral diseases. It seeks to unify RI operations, address regulatory and ethical challenges, and create synergies through common governance. EVORA’s interoperable services will support EU Health-Tech in both inter-crisis and viral emergence response conditions. By establishing a sustainable alliance, EVORA strengthens the cohesiveness of the RI landscape, enhances the European Research Area’s competitiveness, and bolsters the EU’s resilience against emerging communicable diseases.
